StreetInsider.com News Articles

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin Biosciences has completed a $330 million Series B financing round to fund global Phase 3 trials of OLN324, a VEGF/Ang2 bispecific antibody being developed for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), according to a statement from partner Innovent Biologics (HKEX: 01801).

The round was co-led by TCGX and ARCH Venture Partners, with participation from a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board, RA Capital Management, accounts advised by T. Rowe Price Investment Management, and an unnamed sovereign wealth fund. Existing investors Mubadala Capital and Monograph Capital also participated.

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second

Wed, 24 Jun 2026 20:00:00 -0400

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

Proceeds will support global Phase 3 trials of IBI324 (Ollin R&D code: OLN324), a potential best-in-class VEGF/Ang2 bispecific antibody, in $15 billion retina market addressing leading causes of vision loss

OLN324 demonstrated faster and greater retinal drying and numerically greater vision gains versus Vabysmo® in a randomized head-to-head proof of concept JADE clinical trial, as reported earlier this year

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second

Wed, 24 Jun 2026 20:00:00 -0400

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second

Wed, 24 Jun 2026 20:00:00 -0400

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second

Wed, 24 Jun 2026 20:00:00 -0400

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second

Wed, 24 Jun 2026 20:00:00 -0400

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second

Wed, 24 Jun 2026 20:00:00 -0400

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors

SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent